Objective: Autologous hematopoietic stem cell transplantation (aHSCT) is increasingly recognized as a potential therapy for patients with highly active multiple sclerosis (MS). This study aims to assess outcome differences in disease activity in MS patients treated either with aHSCT or alemtuzumab. ...
To confirm CXCL10 over production in bone marrow mesenchymal stem cells (MSCs) and circulating monocytes isolated from multiple sclerosis patients (MS) and identify predate cell molecular signature; to extend this analysis after autologous hematopoietic stem cell transplantation (AHSCT) to test if ...
AHSCT aims to deplete the autoimmune repertoire and generate a new immune system, thereby reestablishing a state of autotolerance, already shown in multiple sclerosis,27, 28 systemic lupus erythematosus,29, 30 juvenile arthritis,31 Crohn disease,32 and SSc.19, 33 In SSc, we previously showed ...
lupus, vasculitis and other connective tissue diseases affect many organs, typically causing inflammation and scarring of the skin, heart, lungs, kidneys and other organs. Multiple sclerosis (MS) affects the brain and spinal cord, whereas Crohn’s disease affects the gut. ...
Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. OBJECTIVE: Systemic sclerosis (SSc) is a generalised autoimmune disease, causing morbidity and a reduced life expectancy, especially in patients with rapid... MC Vonk,Z Marjanovic,dHFHJ...
Objective: To highlight the use of AHSCT to control Relapsing Remitting Multiple Sclerosis (RRMS) after Alemtuzumab treatment failure.Background: Disease modifying therapies (DMT) for RRMS have been the mainstay of treatment for 20 years. Alemtuzumab is one of the most highly efficacious DMT for...
multiple sclerosisstem celltreatmentMultiple sclerosis (MS) is an autoimmune disease odoi:10.3109/00207454.2015.1121388SzczechowskiMedLechMedSmilowskiMedMarekMedHelbigMedGrzegorzMedKyrcz-KrzemienMedSlawomiraMedKrawczyk-KulisMedMalgorzataMedInternational Journal of Neuroscience...
Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis – whom, whenand how: International Journal of Neuroscience: Vol 126, No 10doi:10.3109/00207454.2015.1121388LechDepartmentSzczechowskiDepartmentMarekDepartment
Autologous hematopoietic stem cell transplantation (AHSCT) has been used in the treatment of highly active multiple sclerosis (MS) for over two decades. It has been demonstrated to be highly efficacious in relapsing–remitting (RR) MS patients failing to respond to disease-modifying drugs (DMDs)....
sclerosistreatmentSTEMcelltransplantationAUTOTRANSPLANTATIONA letter to the editor is presented in response to the article "Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial," by Harold L. Atkins and colleagues in...